About US
Contact us
-
Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battleNovartis CEO Joe Jimenez today pointed to the company’s biosimilars program as being one buffer if President Trump’s threat to cut drug prices should materialize into some action. The drugmaker has tw2017/2/15
-
Government still has 'no settlement' with Mylan, CMS administrator saysLast fall, Mylan announced it had reached a swift settlement with the U.S. Department of Justice over allegedMedicaid misclassifications on thebig-selling EpiPen. But now, a top U.S. health official s2017/2/14
-
Is Praluent doomed? Regeneron, Sanofi appeal for a reprieve, but experts are skepticalSanofi and Regeneron have made their bid for a Praluent reprieve. In the wake of a district judge’s patent ruling that could push the partners’ new cholesterol drug off the market, the two companies a2017/2/14
-
Supreme Court takes up Amgen, Sandoz's market-defining biosimilars disputeThe U.S. Supreme Court will take on a closely watched legal skirmish between Amgen and Novartis’ Sandoz, with the outcome set to define launch timelines across the budding biosim field. The Supreme2017/2/13
-
Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with ForwardBiogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash. And if Forward wins particular patent rights on its rival drug, Biogen will be on the ho2017/2/13
-
Eli Lilly's Alimta escapes early generics—and a sales hit—with patent win over TevaChalk up a win for Eli Lilly in a much-watched patent tussle over the blockbuster cancer med Alimta. A federal appeals court said generic versions from Teva and others would step on a key Lilly patent2017/2/10
-
Amid insulin market scrutiny, Novo faces class action alleging 'collusive price fixing'While all of biopharma felt the sting of tough talk from President-elect Donald Trump on Wednesday, Novo Nordisk faced some fresh concerns of its own. A New York law firm said it filed aclass actionsu2017/2/10
-
Regeneron CEO: Amgen's disruptive Praluent-blocking patent move hurts patientsSAN FRANCISCO—Last week, a U.S. District Courtblocked salesof Sanofi and Regeneron’s PCSK9 med, Praluent, as part of an ongoing patent war with Repatha-maker Amgen. And Monday at the J.P. Morgan Healt2017/2/9
-
J&J and Actelion reportedly take complicated deal to Swiss regulator for rulingThere is evidence that Actelion and Johnson & Johnson are edging closerto a deal to give the U.S. drugmaker control of the Swiss biotech, sort of. Citing a report in the Swiss newspaper Tages-Anz2017/2/9
-
Sanofi and Regeneron ordered to halt Praluent sales, but companies to appeal judge's decisionA U.S. federal judge handed Sanofi and partner Regeneron a stunning loss with a ban on sales of their cholesterol-lowering drug Praluent in the U.S. after a jury said it infringed Amgen’s patent for r2017/2/8